Perturbational complexity index in assessing responsiveness to rTMS treatment in patients with disorders of consciousness: a cross-over randomized controlled trial study.

The sample size was small (20 patients), limiting the generalizability of the findings. All patients received multiple concurrent interventions (routine medication, nursing, and various rehabilitation therapies). The study cannot determine the specific contribution of rTMS alone versus the combined effect of all treatments. The localization of the stimulation target (L-DLPFC) was based on the EEG 10-20 system (F3) rather than MRI navigation, which may result in less precise targeting. The study only included patients with MCS, so findings may not apply to those with vegetative state/unresponsive wakefulness syndrome (VS/UWS) or other disorders of consciousness. The primary outcome (CRS-R) is a behavioral measure subject to inter-rater variability, although blinding was attempted.

The study was funded by the National Natural Science Foundation of China and the Key Technologies R&D Program of Guangdong Province. No specific conflicts of interest with commercial entities selling the rTMS device were declared in the provided text, though the device manufacturer (Jiangxi Brain Modulation Technology Development Co. Ltd.) is named.

Do not conclude that rTMS alone caused the improvement in consciousness. All patients received routine medication and a comprehensive package of rehabilitation therapies (including physical, occupational, and speech therapy components) concurrently. The study design cannot separate the effect of rTMS from the effect of these other treatments.